Double stranded-RNA-mediated activation of P21 gene induced apoptosis and cell cycle arrest in renal cell carcinoma
Version of Record online: 18 FEB 2009
Copyright © 2009 UICC
International Journal of Cancer
Volume 125, Issue 2, pages 446–452, 15 July 2009
How to Cite
Whitson, J. M., Noonan, E. J., Pookot, D., Place, R. F. and Dahiya, R. (2009), Double stranded-RNA-mediated activation of P21 gene induced apoptosis and cell cycle arrest in renal cell carcinoma. Int. J. Cancer, 125: 446–452. doi: 10.1002/ijc.24370
- Issue online: 12 MAY 2009
- Version of Record online: 18 FEB 2009
- Accepted manuscript online: 18 FEB 2009 12:00AM EST
- Manuscript Accepted: 30 JAN 2009
- Manuscript Received: 18 NOV 2008
- Veterans Affairs Merit Review
- Veterans Affairs Research Enhancement Award Program (REAP)
- NIH. Grant Numbers: RO1CA111470, RO1CA101844, RO1CA130860, T32DK007790
- renal cell carcinoma;
Small double stranded RNAs (dsRNA) are a new class of molecules which regulate gene expression. Accumulating data suggest that some dsRNA can function as tumor suppressors. Here, we report further evidence on the potential of dsRNA mediated p21 induction. Using the human renal cell carcinoma cell line A498, we found that dsRNA targeting the p21 promoter significantly induced the expression of p21 mRNA and protein levels. As a result, dsP21 transfected cells had a significant decrease in cell viability with a concomitant G1 arrest. We also observed a significant increase in apoptosis. These findings were associated with a significant decrease in survivin mRNA and protein levels. This is the first report that demonstrates dsRNA mediated gene activation in renal cell carcinoma and suggests that forced over-expression of p21 may lead to an increase in apoptosis through a survivin dependent mechanism. © 2009 UICC.
Small double stranded RNAs (dsRNA) are a new class of molecules which have potent effects on gene expression. They are mainly known for their ability to down-regulate gene expression by targeting specific mRNA sequences for degradation, an action which has been coined RNA interference (RNAi).1, 2 More recently, dsRNAs have also been shown to up-regulate gene expression by targeting promoters of genes of interest in a sequence specific fashion, a phenomenon termed RNA activation (RNAa).3 Potential therapeutic options for dsRNA are broad.4, 5 One active area of research is in the treatment of various cancers. Authors have proposed that RNAi could be used to abrogate the effects of a gain of function mutation or overexpressed gene,6 whereas RNAa could be used to increase the expression of tumor suppressor genes.7
Tumorigenesis is dysregulation of the balance between cellular proliferation and programmed cell death, usually in the form of apoptosis. Cellular proliferation is under the control of the cell cycle and its various critical checkpoints that are regulated by cyclin dependent kinases and cyclin dependent kinase inhibitors (CDKIs).8 The ability of CDKIs to negatively regulate progression through the cell cycle lead to their consideration as potential tumor suppressors. The p21WAF1/CIP1 (p21) gene is a CDKI with multiple actions. Induction of p21 predominantly leads to G1 and G29 as well as S-phase arrest.10 p21 may also have contradictory effects on apoptosis. Although it may act in normal settings to prevent programmed cell death, there are also many studies showing that forced expression may increase apoptosis.11
Interestingly, recent data suggests that p21 may have specific effects in renal cell carcinoma, with higher levels of p21 being associated with improved outcome in patients with localized disease.12 Although, recent reports have confirmed the potential tumor suppressor effect of dsRNA mediated p21 gene activation in different cancer cell lines,3, 7, 13, 14 none of these reports have investigated the action of dsRNA gene activation in renal cell carcinoma. Furthermore, whereas two of these studies have shown an increase in both early and late apoptotic cells following dsP21 transfection,7, 15 the mechanism by which p21 leads to apoptosis is not well defined.
SurvivinBirc5 (survivin) is a human inhibitor of apoptosis. Increased survivin levels have been associated with worse prognosis in multiple cancers.16–18 In addition, RNAi has been used to decrease survivin levels and induce apoptosis.19 p21 prevents phosphorylation of the retinoblastoma proteins leading to an accumulation of hypophosphorylated pRB-E2F complex, which may suppress survivin gene expression.20 Hence, one potential mechanism whereby forced expression of p21 leads to an increase in apoptosis would be through a survivin dependent pathway.
Therefore, the aims of this study were two-fold: to examine the effect of RNAa in renal cell carcinoma and to study the effects of dsP21 mediated p21 gene activation on apoptosis and survivin expression.
Material and methods
The design of dsRNA was performed as previously described.3 Synthesis of dsRNA was performed by a commercial biotechnology company (Invitrogen, Carlsbad, CA). A dsRNA (dsP21) targeting the p21 promoter at position-322 relative to the transcription start site (CCA ACU CAU UCU CCA AGU A[dT][dT]) and a control dsRNA (dsCON) lacking significant homology with any other human sequences (ACU ACU GAG UGA CAG UAG A[dT][dT]) were used in this study.
Cell culture and transfection
The human kidney cancer cell line A-498 (American Type Culture Collection, Manassas, VA) was grown in Eagle's Minimum Essential Medium containing 10% fetal bovine serum, penicillin (100 U/mL) and streptomycin (100 μg/mL). The cell line was incubated at 37°C in a humidified atmosphere of 5% CO2. The day before transfection, cells were plated in growth medium without antibiotics in 6-well plates at a density of 30%. dsRNAs were transfected at a concentration of 50 nmol/L using Lipofectamine 2000 reagent (Invitrogen, Carlsbad, CA) according to the manufacturer's instructions. Twenty-four hours after transfection the media was changed to antibiotic containing media. Treatments with dsRNA proceeded for 72 hr before cell harvest.
RNA isolation and RT-PCR
Total cellular RNA was isolated using the RNeasy Mini Kit (Qiagen, Valencia, CA) according to the manufacturer's protocol. Using one microgram of RNA, cDNA synthesis was performed with the Reverse Transcription System with oligo (dT) primers (Promega, Madison, WI). cDNA amplification was performed by PCR using the p21 gene specific primers GCCCAGTGGACAGC GAGCAG (sense) and GCCGGCGTTTGGAGTGGTAGA (antisense). Reaction conditions included an initial denaturation step (94°C for 2 min), 26 cycles of denaturation (94°C for 20 sec), annealing (58°C for 20 sec) and extension (72°C for 30 sec) and was followed by a final incubation at 72°C for 5 min. Amplification of GAPDH was used as an endogenous control for equal RNA loading.
Real-Time PCR was performed using the 7500 Fast Real-Time System (Applied Biosystems, Foster City, CA) in conjunction with gene specific TaqMan assay kits (Applied Biosystems, Foster City, CA) for p21, birc5, and GAPDH. GAPDH was used as an endogenous control to normalize expression. Each sample was analyzed in quadruplicate. Relative expression and standard error were calculated by the supplied Fast 7500 Real-Time System software.
Protein isolation and Western blotting analysis
Attached cells were washed with cold phosphate buffered saline (PBS) and lysed by adding an extraction buffer (M-PER Mammalian Protein Extraction Reagent, Pierce Biotechnology, Rockford, IL). The resulting cell lysate was collected and centrifuged at 15,000g for 15 min at 4°C. Protein concentration was determined in the supernatant fraction with protein assay reagent (Bio-Rad Laboratories, Hercules, CA), using bovine serum albumin as a standard.
For Western blot analysis, protein (40 μg) was denatured under reducing conditions. Protein was separated on 7.5–15% sodium dodecyl sulfate polyacrylamide gels with pre-stained protein molecular weight standards. The separated proteins were then electroblotted on 0.45 μm nitrocellulose membranes by voltage gradient transfer (Bio-Rad Laboratories, Hercules, CA). Blots were blocked with 5% non-fat dry milk and washed twice with 1.0% PBS; 0.1% Tween buffer. Antibodies used in detection were anti-p21/KIP1 (C-19, 1:1,000) (Santa Cruz Biotechnology, Santa Cruz, CA), anti-birc5 (D-8, 1:500) (Santa Cruz Biotechnology, Santa Cruz, CA) and anti-GAPDH mouse monoclonal (MAB-374, 1:5,000) (Chemicon International-Millipore, Billerica, MA). GAPDH was used as a protein loading control. Immunodetection was followed by incubation with an anti-mouse IgG, HRP-linked antibody (Cell Signaling, Danvers, MA). Antigen–antibody complexes were visualized by chemi-luminescence (Santa Cruz Biotechnology, Santa Cruz, CA).
Cell proliferation assay
Cell proliferation was investigated using the CellTiter 96 AQueous One Solution Cell Proliferation Assay kit (Promega, Madison, WI). Twenty-four hours after transfection, attached cells were trypsinized and then subcultured in 96-well plates containing the transfection mixture at a concentration of 1 × 105 cells/mL following dilution with antibiotic containing medium. Incubation occurred for 72 hr. At end of the incubation, 20 μL of CellTiter 96 AQueous One Solution was added to each well. After one hour, the absorbance at 490 nm was measured on an ELISA reader (Bio-Tek Instruments, Winooski, VT).
Analysis of DNA content by flow cytometry
Media containing the floating cell population was collected from transfected A498 cells. Subsequently, the attached cells at a concentration 1 × 106 cells/mL were trypsinized and combined with the detached cells. The samples were centrifuged at 2,500g and 4°C for 5 min and washed in PBS. The pellet was gently resuspended in 1 mL of cold saline GM solution (6.1 mM glucose, 1.5 mM NaCl, 5.4 mM KCl, 1.5 mM Na2HPO4, 0.9 mM KH2PO4, 0.5 mM EDTA). The cells were fixed with 5 mL of 70% cold (−20°C) ethanol overnight. Cells were then washed once at 1,500g for 5 min in PBS with 5mM EDTA and resuspended in 1 mL of propidium iodide (PI) staining solution (30 μg/mL PI, 300 μg/mL RNAse A in 1 × PBS). Cells were stained for 1 hr at room temperature in the dark and subsequently filtered through 30 μM nylon mesh. Analysis was performed on a FACScan flow cytometer (Becton Dickinson, Franklin Lakes, NJ). Events (10,000) were collected and PI intensity was analyzed using the FL2 channel for relative DNA content. Forward and side scatter gates and a doublet discrimination plot were set to include whole and individual cell populations, respectively. The resulting data was analyzed to determine cell cycle distribution.
Annexin V apoptosis assay
Media containing the floating cell population was collected from transfected A-498 cells. Subsequently, the attached cells at a concentration 1 × 105 cells/mL were trypsinized and combined with the floating cells. The samples were centrifuged at 2,500g and 4°C for 5 min and washed in PBS. Annexin V-FITC and PI staining were then carried out using the Apoptosis Detection Kit (BioVision, Mountain View, CA). The cells were observed under a fluorescence microscope using a dual filter for FITC and rhodamine. Cells undergoing early apoptosis were FITC+ PI−. Cells undergoing late apoptosis were FITC+ PI+. A minimum of 100 cells were counted for each group.
A dsRNA targeting the p21 promoter induces p21 expression in kidney cancer cells
Seventy-two hours after transfection with dsP21, mRNA and protein expression were evaluated. As shown in Figure 1a, transfection with dsP21 compared with mock and dsCON transfections readily induced the expression of the target gene p21. Furthermore, Figure 1b shows that a statistically significant (p < 0.001) six-fold induction in p21 mRNA expression occurs. The increase in p21 message was further evaluated by Western blot analysis. As can be seen in Figure 1c, the elevated levels of p21 protein strongly correlated to the increase in p21 mRNA expression.
Transfection with dsP21 inhibits kidney cancer cell proliferation
Following transfection with dsP21, a dramatic decrease in growth rate occurs so that by three days plate density is approximately 50%, compared with 100% in the mock and dsCON transfected groups. These results are shown in Figure 2a. In addition, a distinct phenotypic change occurs with the dsP21 transfected cells assuming an enlarged and flattened cellular morphology consistent with a senescent phenotype, shown in Figure 2b. Further quantitation was performed using the MTT assay. As shown in Figure 2c, at 72 hr transfection with dsP21 was associated with a statistically significant (p = 0.0004) four-fold decrease in cell viability compared with mock or dsCON transfections.
Transfection with dsP21 induces G1 phase arrest and apoptosis in kidney cancer cells
The effect of p21 activation following transfection with dsP21 was examined by determining the relative DNA content of PI stained cells using flow cytometry analysis (FCA). The results of FCA can be found in Figures 3a, 3b. This revealed a statistically significant increase in the G1 population in dsP21 transfected A498 cells compared with mock and dsCON transfections (76 vs. 65%, p = 0.01). Furthermore, a decrease in the S-phase fraction was seen (10 vs. 18%, p = 0.001). No change was seen in the G2/M phase population (15 vs. 15%, p = 0.43). Transfection with dsP21 also caused an increase in the sub-G0/G1 population (11 vs. 0.8%, p = 0.0001) suggestive of an increase in apoptosis. Subsequently, this increase in apoptosis after dsP21 transfection was confirmed by Annexin V staining. An increase in both early apoptosis (9 vs. 1%, p < 0.001) and late apoptosis (12 vs. 1%, p < 0.001) were seen. A representative sample set is shown in Figure 4.
Following transfection with dsP21 a decrease in survivin expression is seen
The effect of p21 activation on survivin message and protein were examined by real time PCR and Western blot analysis. As shown in Figure 5, transfection with dsP21 compared with mock was associated with a nearly eight-fold decrease in survivin message which was statistically significant (p < 0.02). Although a decrease in survivin levels was also seen with dsCON transfection compared with mock, this was not statistically significant (p = 0.51). The decrease in survivin message was further evaluated by Western blot analysis. As can be seen in Figure 5b, forced activation of p21 strongly correlated to a decrease in survivin protein compared with both mock and dsCON transfection.
Small dsRNA mediated gene regulation is a promising new area for the treatment of many diseases and is currently in clinical trials in diseases of the eye and lung in the form of RNAi.21 However, whereas the specificity and high efficacy of RNAi are advantageous, this method is somewhat limited as a therapeutic to disease states with gain of function mutations or increase in copy number. In this regard, RNAa offers options for the many tumors with dysregulated tumor suppressor genes. Two studies have confirmed that RNAa can be used in bladder cancer cell lines to disrupt tumor phenotype and growth rate.7, 15 The purpose of this study was to examine whether these findings were applicable to other types of cancer, in particular renal cell carcinoma, and to expand upon the mechanism by which increased p21 expression leads to cell cycle arrest and induction of apoptosis.
Previous results have shown that dsRNA mediated gene activation takes place between 48 and 72 hr after transfection and that upregulation of target genes last for almost 2 weeks.3 Furthermore, prior experiments demonstrate that the effects of dsRNA activation are not related to dsRNA protein kinase activation or a non-specific interferon response.3 However, a differential susceptibility to RNAa by cell line and target gene of interest has been observed.3 The present study showed for the first time that RNAa is successful in human renal cell carcinoma. More specifically, the A498 kidney cancer cell line is susceptible to a dsP21 mediated increase in p21 mRNA and protein expression. In fact, the six-fold induction in p21 mRNA expression is quite robust in comparison with results of other RNAa experiments.
Furthermore, transfection with dsP21 and subsequent induction of p21 protein expression led to a significant decrease in A498 cell viability and the assumption of a senescent phenotype. Similar results have been shown for ectopic expression of p21 or induction of p21 by different mechanisms.22–27 Concomitantly, results of flow cytometry showed that dsP21 transfection caused a G1 arrest, with a significant decrease in S-phase. This is a somewhat expected result given the role of p21 as a CDKI, and in particular CKD4, which is a main regulator of cell cycle progression through G1. However, these findings highlight the potent effects that can be mediated through RNAa of tumor suppressor genes.
Although previously observed, the findings of a significant number of floating cells and cells which assume a senescent phenotype continues to be a somewhat unexpected result of forced p21 expression. The role of p21 in apoptosis is controversial, with many studies showing the contradictory findings of both promotion and inhibition of apoptosis.11 What seems clear is that the effects of p21 vary depending on cell line,28, 29p53 status30 and cause of p21 activation.31 In general, direct targeting of p21 activation has been shown to induce apoptosis. In this study, Annexin V staining was used to show an increase in both early and late apoptosis.
One potential pathway for p21 mediated apoptosis is through a survivin dependent mechanism. Regulation of survivin is under the control of the RB/E2F family of proteins, which in turn are controlled by p21.32 The known abnormalities in the A498 cell line involve the hypoxia inducible factor pathway, and there are no known mutations in the RB or E2F genes. Through quantitative PCR and Western blot analysis, we showed that following transfection with dsP21 there is a statistically significant decrease in both survivin message and protein. This association will need to be explored in future studies to determine causality.
This study was supported by Veterans Affairs Merit Review, Veterans Affairs Research Enhancement Award Program (REAP) and NIH grants: RO1CA111470, RO1CA101844, RO1CA 130860 and T32DK007790 (to R.D.).